Changing temporal trends in non-AIDS cancer mortality among people diagnosed with AIDS: San Francisco, California, 1996-2013.

[1]  E. Williams,et al.  Alcohol Use and Human Immunodeficiency Virus (HIV) Infection: Current Knowledge, Implications, and Future Directions. , 2016, Alcoholism, clinical and experimental research.

[2]  D. Serraino,et al.  Non–AIDS-Defining Cancer Mortality: Emerging Patterns in the Late HAART Era , 2016, Journal of acquired immune deficiency syndromes.

[3]  S. Ishikawa,et al.  Accuracy of Death Certificates and Assessment of Factors for Misclassification of Underlying Cause of Death. , 2016, Journal of epidemiology.

[4]  S. Garland,et al.  Anal HPV detection in men who have sex with men living with HIV who report no recent anal sexual behaviours: baseline analysis of the Anal Cancer Examination (ACE) study , 2015, Sexually Transmitted Infections.

[5]  G. Copeland,et al.  Rectal squamous cell carcinoma in immunosuppressed populations: is this a distinct entity from anal cancer? , 2015, AIDS.

[6]  K. Straif,et al.  Alcohol consumption and liver cancer risk: a meta-analysis , 2015, Cancer Causes & Control.

[7]  J. Margolick,et al.  Lung cancer incidence and survival among HIV-infected and uninfected women and men , 2015, AIDS.

[8]  K. SchwarczSandra,et al.  Changes in Causes of Death Among Persons with AIDS: San Francisco, California, 1996–2011 , 2014 .

[9]  O. Kirk,et al.  Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration , 2014, The Lancet.

[10]  Theodore J. Iwashyna,et al.  Death Certificates Underestimate Infections as Proximal Causes of Death in the U.S , 2014, PloS one.

[11]  P. Morlat,et al.  Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000 , 2014, AIDS.

[12]  J. Sterne,et al.  Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Jackson,et al.  Comparative Outcomes of Chemotherapy with and without HAART for HIV-Related B-Cell Lymphoma: A Meta-Analysis , 2013 .

[14]  R. Weber,et al.  Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study , 2013, HIV medicine.

[15]  H. Weir,et al.  The impact of National Death Index linkages on population-based cancer survival rates in the United States. , 2013, Cancer epidemiology.

[16]  D. Klein,et al.  Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons , 2012, AIDS.

[17]  A. Del Arco,et al.  Lung cancer in HIV-infected patients , 2012, International journal of STD & AIDS.

[18]  Melonie P. Heron,et al.  Impact of using multiple causes of death codes to compute site-specific, death certificate-based cancer mortality statistics in the United States. , 2012, Cancer epidemiology.

[19]  S. Silva,et al.  HIV, EBV and KSHV: Viral cooperation in the pathogenesis of human malignancies , 2011 .

[20]  A. Justice,et al.  Cancer Screening in Patients Infected with HIV , 2011, Current HIV/AIDS reports.

[21]  J. Goedert,et al.  Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. , 2011, JAMA.

[22]  C. Flexner,et al.  Emerging antiretroviral drug interactions. , 2011, The Journal of antimicrobial chemotherapy.

[23]  S. Deeks,et al.  HIV infection, inflammation, immunosenescence, and aging. , 2011, Annual review of medicine.

[24]  J. Goedert,et al.  Pulmonary Infections and Risk of Lung Cancer Among Persons With AIDS , 2010, Journal of acquired immune deficiency syndromes.

[25]  E. Simard,et al.  Cancer as a cause of death among people with AIDS in the United States. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  J. Weber,et al.  Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission , 2010, AIDS.

[27]  Ross J. Harris,et al.  Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  D. Saslow,et al.  Cancer Screening in the United States, 2010: A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening , 2010, CA: a cancer journal for clinicians.

[29]  E. Engels.  Non-0002030-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities , 2009, AIDS.

[30]  J. Justman,et al.  Screening HIV-infected patients for non-AIDS-defining malignancies , 2009, Current HIV/AIDS reports.

[31]  P. Sullivan,et al.  Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. , 2008, Annals of internal medicine.

[32]  J. Neaton,et al.  Risk of cancers during interrupted antiretroviral therapy in the SMART study , 2007, AIDS.

[33]  D. Vlahov,et al.  HIV infection is associated with an increased risk for lung cancer, independent of smoking. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  Melissa R Pfeiffer,et al.  Causes of Death among Persons with AIDS in the Era of Highly Active Antiretroviral Therapy: New York City , 2006, Annals of Internal Medicine.

[35]  F. Miedema,et al.  Long-Term Highly Active Antiretroviral Therapy in Chronic HIV-1 Infection: Evidence for Reconstitution of Antiviral Immunity , 2006, Antiviral therapy.

[36]  D. Boothroyd,et al.  HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations , 2005, AIDS.

[37]  R. Pfeiffer,et al.  Survival After Cancer Diagnosis in Persons With AIDS , 2005, Journal of acquired immune deficiency syndromes.

[38]  P. Sinibaldi-Vallebona,et al.  Inhibition of endogenous reverse transcriptase antagonizes human tumor growth , 2005, Oncogene.

[39]  C. Boshoff,et al.  Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia , 2004, AIDS.

[40]  A. McNaghten,et al.  Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. , 2003, The Journal of infectious diseases.

[41]  R. Chung,et al.  Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  A. Kennedy.  Chemopreventive agents: protease inhibitors. , 1998, Pharmacology & therapeutics.

[43]  J. Palefsky,et al.  High incidence of anal high‐grade squamous intra‐epithelial lesions among HIV‐positive and HIV‐negative homosexual and bisexual men , 1998, AIDS.

[44]  S. Fedewa,et al.  Cancer screening in the United States, 2015: A review of current American Cancer Society guidelines and current issues in cancer screening , 2015, CA: a cancer journal for clinicians.

[45]  Matthew J Hayat,et al.  Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. , 2007, The oncologist.